Signalling its intent to stay at the head of the cellular immunotherapy field, Juno Therapeutics has agreed to collaborate with genome editing specialist Editas Medicine to create next-generation chimeric antigen receptor (CAR-T) and high-affinity T cell receptor (TCR) therapies for the treatment of cancer. With the deal, Juno will leverage Editas’ CRISPR (clustered, regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) technology with the aim of expanding its pipeline into solid tumours.